1-(3-氯丙基)哌啶-4-醇 | 145285-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(3-氯丙基)哌啶-4-醇
• 英文名称: 1-(3-chloro-propyl)-piperidin-4-ol
• 英文别名: 1-(3-Chloropropyl)piperidin-4-OL
• CAS: 145285-36-5
• 化学式: C₈H₁₆ClNO
• 分子量: 177.674
• InChiKey: ADLTVEOBDGHJHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  8-chloro-spiro--2',5'-dione 、 1-(3-氯丙基)哌啶-4-醇 在 sodium hydride 作用下， 生成 8-chloro-1'-[3-(4-hydroxypiperidino]propyl]spiro[chroman-4,4'-imidazolidine]-2',5'-dione
  参考文献：
  名称：

  Synthesis and Antiarrhythmic Activity of 2,2-Dialkyl-1'-(N-substituted aminoalkyl)-spiro-(chroman-4,4'-imidazolidine)-2',5'-diones.

  摘要：

  合成了一系列新型的2, 2-二烷基-1'-(N-取代氨基烷基)-螺-[色满-4, 4'-咪唑烷]-2', 5'-二酮化合物，并评估了其在氯仿或/和乌头碱诱导的小鼠心室心律失常中的抗心律失常活性。在这些化合物中，(-)-6-氯-2, 2-二甲基-1'-[3-(4-羟基哌啶基)丙基]-螺-[色满-4, 4'-咪唑烷]-2', 5'-二酮被发现比参考药物更有效，并被选作进一步开发。

  DOI：

  10.1248/cpb.40.1823
• 作为产物：
  描述：

  4-羟基哌啶 、 sodium hydroxide 、 1-溴-3-氯丙烷 以 丙酮 为溶剂， 以to give the title compound (1.5 g, 28%) as a pale yellow oil的产率得到1-(3-氯丙基)哌啶-4-醇
  参考文献：
  名称：

  3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands

  摘要：

  本发明涉及式（I）的3或4-单取代苯酚和噻吩酚衍生物，以及用于制备、制备中间体、含有和使用此类衍生物的组合物的过程。所述的3或4-单取代苯酚和噻吩酚衍生物是H3配体，可用于许多疾病、障碍和病况，特别是炎症性、过敏性和呼吸系统疾病、障碍和病况。

  公开号：

  US07456164B2

文献信息

• 3- Or 4-monosubstituted phenol derivatives useful as H3 ligands
  申请人：Warner-Lambert Company LLC

  公开号：EP1593679A1

  公开（公告）日：2005-11-09

  The invention relates to 3- or 4-monosubstituted phenol derivatives and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol derivatives are H3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  这项发明涉及3-或4-单取代酚衍生物，以及用于制备、制备中间体、含有和使用这些衍生物的过程。所述的3-或4-单取代酚衍生物是H3配体，在许多疾病、紊乱和状况中非常有用，特别是炎症性、过敏性和呼吸系统疾病、紊乱和状况。
• Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity
  作者：Hao Yang、Fang-Ting Wang、Min Wu、Wenjie Wang、Keli Agama、Yves Pommier、Lin-Kun An

  DOI：10.1016/j.bioorg.2022.105789

  日期：2022.6

  Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme that repairs DNA lesions caused by the trapping of DNA topoisomerase IB (TOP1)-DNA break-associated crosslinks. TDP1 inhibitors have synergistic effect with TOP1 inhibitors in cancer cells and can overcome cancer cell resistance to TOP1 inhibitors. Here, we report the synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as selective

  酪氨酰-DNA 磷酸二酯酶 1 (TDP1) 是一种酶，可修复因捕获 DNA 拓扑异构酶 IB (TOP1)-DNA 断裂相关交联而引起的 DNA 损伤。 TDP1抑制剂与癌细胞中的TOP1抑制剂具有协同作用，可以克服癌细胞对TOP1抑制剂的耐药性。在这里，我们报道了作为选择性 TDP1 抑制剂的 11-氨基烷氧基取代的苯并菲啶衍生物的合成，并表明六种化合物14 、 16 、 18 、 20 、 25和27表现出高 TDP1 抑制效力。最有效的 TDP1 抑制剂14 (IC 50 = 1.7 ± 0.24 μM) 可诱导细胞 TDP1cc 形成，并在四种人类癌细胞系 MCF-7、A549、H460 和 HepG2 中与拓扑替康显示出协同作用。
• 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands
  申请人：Bernardelli Patrick

  公开号：US20050267095A1

  公开（公告）日：2005-12-01

  The invention relates to 3- or 4-monosubstituted phenol and thiophenol derivatives of formula (I) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. Said 3- or 4-monosubstituted phenol and thiophenol derivatives are H 3 ligands and are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  本发明涉及公式(I)的3-或4-单取代苯酚和硫代苯酚衍生物，以及用于制备这些衍生物的中间体、含有这些衍生物的组合物和这些衍生物的用途的过程。所述的3-或4-单取代苯酚和硫代苯酚衍生物是H3配体，在许多疾病、失调和病况中特别有用，特别是在炎性、过敏和呼吸系统疾病、失调和病况中。
• 3-Aminoindazole derivatives and process for preparation thereof
  申请人：Asahi Kasei Kogyo Kabushiki Kaisha

  公开号：EP0049779A1

  公开（公告）日：1982-04-21

  A compound of the formula (I): wherein W, is a hydrogen atom or a group wherein Y is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R, and R2 each independently is a hydrogen atom or a C1-6 alkyl group and R,, R2 and the adjacent nitrogen atom may form a C4-6 heterocyclic ring or a C4-6 heterocyclic ring containing an additional nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; W2 is a hydrogen atom or a group wherein Z is a C1-6 alkylene group or a C1-6 alkylene group having a C1-6 alkyl group substituent; and R3 and R4 each independently is a hydrogen atom or a C1-6 alkyl group and R3, R4 and the adjacent nitrogen atom may form a C4-6 hetercyclic ring or a C4-6 heterocyclic ring containing an additional nitrogen atom and the C4-6 heterocyclic rings may have at least one C1-6 alkyl group, hydroxyl group or halogen atom; when W, is a hydrogen atom, W2 is the group; and when W2 is a hydrogen atom, W, is the group; and the pharmaceutically acceptable acid addition salt thereof.

  式 (I) 的化合物： 其中 W，是氢原子或 其中 Y 是 C1-6 亚烷基或具有 C1-6 烷基取代基的 C1-6 亚烷基；R 和 R2 各自独立地是氢原子或 C1-6 烷基，且 R、R2 和相邻的氮原子可形成 C4-6 杂环或含有额外氮原子的 C4-6 杂环，且 C4-6 杂环可具有至少一个 C1-6 烷基、羟基或卤素原子； W2 是氢原子或 其中 Z 为 C1-6 亚烷基或具有 C1-6 烷基取代基的 C1-6 亚烷基；以及 R3 和 R4 各自独立地为氢原子或 C1-6 烷基，且 R3、R4 和相邻氮原子可形成 C4-6 杂环或含有额外氮原子的 C4-6 杂环，且 C4-6 杂环可具有至少一个 C1-6 烷基、羟基或卤素原子； 当 W 是氢原子时，W2 是 基团；以及 当 W2 是氢原子时，W, 是基团；及 基团；及其药学上可接受的酸加成盐。
• Synthesis and Biological Evaluation of Novel Sigma-1 Receptor Antagonists Based on Pyrimidine Scaffold As Agents for Treating Neuropathic Pain
  作者：Yu Lan、Yin Chen、Xudong Cao、Juecheng Zhang、Jie Wang、Xiangqing Xu、Yinli Qiu、Tan Zhang、Xin Liu、Bi-Feng Liu、Guisen Zhang

  DOI：10.1021/jm501207r

  日期：2014.12.26

  The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (sigma R-1) antagonists, associated with pharmacological antineuropathic pain activity, are the focus of this article. The new compounds were evaluated in vitro in sigma-1 and sigma-2 receptor binding assays. The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model. The most promising derivative was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (137), which exhibited a high binding affinity to sigma R-1 receptor (K-i sigma(1) = 1.06 nM) and good sigma-1/2 selectivity (1344-fold). In in vivo tests, compound 137 exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain. In addition, no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted. These data suggest compound 137 may constitute a novel class of drugs for the treatment of neuropathic pain.